In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
News|Articles|July 17, 2026
Hereditary Hemochromatosis: A Preventable Burden Hidden in Plain Sight
Author(s)Maggie L. Shaw
Fact checked by: Laura Joszt, MA
A common, underdiagnosed genetic disorder, hereditary hemochromatosis is costly when caught late and simple to treat when caught early.
Advertisement
Advertisement
One of the most common inherited genetic disorders in the US is quietly driving cirrhosis, heart failure, and diabetes as well as years of unnecessary specialist care, all largely preventable with a blood test and a timely diagnosis, according to Usha Perepu, MD, a nationally recognized classical hematology expert and director of classical hematology at the Mays Cancer Center at UT Health San Antonio.
Related to this article
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.
Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement